DEF 14C: Propanc Biopharma Secures Capital via Convertible Preferred Stock

Propanc Biopharma, Inc. announced a private placement of Series C Preferred Stock and Warrants to Hexstone Capital LLC, approved by majority stockholder consent.

Summary

• Propanc Biopharma, Inc. entered into a Securities Purchase Agreement (SPA) with Hexstone Capital LLC on October 7, 2025, for a private placement.
• The company issued 100 shares of Series C Preferred Stock and a Warrant to purchase up to an additional 9,900 shares of Series C Preferred Stock.
• Each share of Series C Preferred Stock has a stated value of $10,000 and is convertible into common stock at the lesser of a fixed conversion price of $5.00 per share or 85% of the lowest trading price of the Common Stock during a specified period, subject to a five-trading day minimum.
• The transaction was approved by the Board of Directors and the Majority Stockholder (James Nathanielsz, holding approximately 79.77% of the total voting equity) via written consent on October 7, 2025.
• Stockholder approval was required to comply with NASDAQ Listing Rules 5635(b) and 5635(d) due to the potential for a change of control and the issuance of 20% or more of common stock at a discount.
• The Information Statement is expected to be mailed on or about December 29, 2025, with the corporate action becoming effective 20 calendar days after the mailing date.

Sentiment

Score: 3

Explanation: The capital raise provides necessary funding but comes with highly dilutive terms for existing common shareholders due to variable conversion prices tied to low trading prices, indicating significant downside risk for common equity.

Positives

• Secured capital through a private placement with Hexstone Capital LLC, providing funding for the company.
• Maintained compliance with NASDAQ listing rules by obtaining majority stockholder approval for the transaction, preventing potential delisting issues.

Negatives

• The Series C Preferred Stock has variable conversion terms, allowing conversion at a price equal to 85% of the lowest trading price, which is highly dilutive for existing common stockholders.
• The potential issuance of common stock upon conversion of the Series C Preferred Stock could exceed 20% of the outstanding common stock, leading to substantial dilution.
• The transaction may be deemed a 'change of control' under NASDAQ Listing Rule 5635(b) if the investor acquires 20% or more of the common stock or voting power.

Risks

• Significant dilution of existing common stockholders due to the conversion of Series C Preferred Stock and exercise of Warrants, especially with variable conversion terms tied to low trading prices.
• Potential for the conversion price to be substantially below market value, as per NASDAQ Listing Rule 5635(d), leading to a large number of common shares being issued.
• The variable conversion terms could lead to an issuance of common stock based on a share price of $0.01 or less, as noted in NASDAQ's interpretive material, exacerbating dilution.

Future Outlook

The corporate action, specifically the issuance of Series C Preferred Stock and Warrants, will become effective 20 calendar days after the mailing of this Information Statement. The company remains subject to ongoing NASDAQ listing rules and SEC disclosure requirements.

Management Comments

• "We are not asking you for a proxy, and you are requested not to send us a proxy."

Industry Context

This type of private placement with convertible preferred stock and warrants, especially with variable conversion prices, is often seen in smaller biopharma companies seeking capital for research and development or operational needs. Such structures can be highly dilutive but provide necessary funding when traditional equity financing is challenging. The NASDAQ listing rules compliance highlights the importance of maintaining public market access for such companies.

Comparison to Industry Standards

• The use of convertible preferred stock with variable conversion prices is a common financing mechanism for early-stage or growth-stage biopharma companies, particularly those with limited revenue or significant R&D expenses, where traditional debt or equity financing might be difficult or expensive.
• However, conversion terms tied to a discount of the lowest trading price (e.g., 85% of the lowest trading price) are generally considered highly dilutive and unfavorable for existing common shareholders compared to fixed-price conversions or market-rate equity raises.
• The potential for the issuance to exceed 20% of outstanding common stock, triggering NASDAQ Rule 5635(d), is a standard threshold for significant dilution that requires shareholder approval, which was obtained here.
• The 'change of control' implication under NASDAQ Rule 5635(b) for an investor acquiring 20% or more is a standard regulatory concern for such large issuances, even if it does not constitute a change of control under other legal definitions.

Corporate Governance

Related Party Transactions

• James Nathanielsz, the CEO and Director, is identified as the Majority Stockholder, holding approximately 79.77% of the total voting equity, and approved the Hexstone Transaction via written consent.

Stakeholder Impact

• Shareholders (Common Stock): Significant potential for dilution due to the variable conversion terms of the Series C Preferred Stock and the Warrant, which could lead to common stock being issued at a substantial discount.
• Hexstone Capital LLC: Gains a significant convertible equity position with favorable conversion terms, potentially allowing them to acquire a large stake in the company at a low price.
• Company: Secures capital for operations or development, but at the cost of potentially substantial future dilution for existing common shareholders.

Next Steps

• Mailing of the Information Statement to shareholders on or about December 29, 2025.
• Corporate action (Hexstone Transaction) to become effective 20 calendar days after the mailing of the Information Statement.
• Potential conversion of Series C Preferred Stock into common stock by Hexstone Capital LLC.
• Potential exercise of the Warrant by Hexstone Capital LLC to purchase additional Series C Preferred Stock.

Key Dates

Recommendation

The terms of the private placement, particularly the variable conversion price for the Series C Preferred Stock (lesser of $5.00 or 85% of the lowest trading price), are highly dilutive for existing common shareholders. This structure allows the investor to convert at a deep discount, potentially leading to a massive increase in outstanding common shares and significant value erosion for current equity holders. The potential for the issuance to exceed 20% of common stock, as noted by NASDAQ, underscores the severity of the dilution. While the capital raise provides funding, the cost to common shareholders is exceptionally high, making the common stock a strong sell.

Keywords

Propanc Biopharma, Hexstone Capital, Series C Preferred Stock, Convertible Securities, Private Placement, Warrant, NASDAQ Listing Rules, Dilution, Capital Raise, SEC Filing, DEF 14C